Products/Pipeline
ETUARY®(艾思瑞® in Chinese)
CFDA Class 1.1 Pharmaceutical Drug
ETUARY® (艾思瑞® in Chinese) effectively inhibits the progression of fibrosis in the lungs and kidneys through its antifibrotic, anti-inflammatory, and antioxidant properties.
It helps delay the progression of various conditions, including:
- Idiopathic Pulmonary Fibrosis (IPF), a type of interstitial lung disease with unknown cause
- Radiation pneumonitis, a side effect of radiation therapy, a standard treatment for lung and mediastinal cancers
- Interstitial lung diseases associated with connective tissue disorders
- Diabetic nephropathy, a chronic kidney disease
Clinical development
GNI has been developing drugs in China for the treatment of (1) Idiopathic Pulmonary Fibrosis (IPF), (2) Radiation Pneumonitis (RP), (3) Diabetic Nephropathy (DN), and (4) Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD).
Regarding (1) IPF treatment, new drug approval was obtained in September 2011, followed by manufacturing and marketing authorization in December 2013, with sales commencing in February 2014.
As for (3) DN treatment, phase 1 clinical trials have been completed and discussions with Chinese authorities on future progress are ongoing, while for (4) CTD-ILD, phase 3 clinical trials are ongoing.